问题 › 我们下一步该投哪里？ › 健康科技与数字健康
资本分配出错，通常是因为下一份带风险的合同先签了——销售周期短于观察参与率和归因结果能否支撑份额所需的时间窗口。 数字健康公司面临的具体困境是：结果风险签得比公司能验证自己能否承担的速度更快，12个月的测量窗口对上11个月的销售周期。在这点被定价前，带风险的收入分成会持续因无人能归因的原因变动，关于各条线回报的争论也将一直停留在意见层面。
资本分配出错，通常是因为下一份带风险的合同先签了——销售周期短于观察参与率和归因结果能否支撑份额所需的时间窗口。 数字健康公司面临的具体困境是：结果风险签得比公司能验证自己能否承担的速度更快，12个月的测量窗口对上11个月的销售周期。在这点被定价前，带风险的收入分成会持续因无人能归因的原因变动，关于各条线回报的争论也将一直停留在意见层面。
多数数字健康公司按历史和内部游说分配资源：拿下上一个客户的项目获得下一笔增量，提出最强PMPM扩张故事的团队赢得预算。这两者都与哪条线能提升下一位参保人的毛利率无关。
有效的分析按两件事给每条线排序——增量投资回报率（用带风险收入分成和参与率衡量），以及在考虑客户流失和12个月测量窗口后，该回报还能维持多久。快速提升参与率但在销售周期内丢客户的线，与能跨续约保持归因结果稳定的线，是两种不同命题。
输出应该是一条带停止规则的序列，而不是预算拆分。哪条线先做，下一个美元投在里面什么位置，以及参与率或客户流失出现何种变化时说明序列需要调整。
这三者同时出现才是标志。单独一个通常指向其他问题。
✓ 预算按去年的PMPM目标加一个百分比设定，不再根据当前带风险份额表现重新计算。
✓ 没人能用参与率和毛利率共同给现有项目按增量投资回报率排序。
✓ 投资决策用下一个客户的规模或归因结果的战略重要性辩护，而不是用流失和毛利率的算术。
通常会让情况更糟的做法。 把资本平均撒在各项目以维持内部和平，结果低配了那条参与率和带风险份额本可在测量窗口内复利的线。
It is for you if you run or finance a digital health company and budgets are set by last year plus a percentage. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on 一家数字健康公司. It is a sample profile rather than a customer, and it is engine output translated from English — this is the format you get, on your own numbers.
The subject is Vantabridge Health, a sample company profile used for testing rather than a customer — $62M ARR, 340,000 enrolled members.
Excerpt from a real Percision run · Customer Value Architecture · sample company profile
The move. Reduce downside exposure from $7.1M outcomes shortfall to $4.2M while maintaining upside participation in 34 health-plan contracts.
The leak it closes. $2.9M gross profit protected annually through downside cap (difference between $7.1M shortfall at 38% vs $4.2M shortfall at 25%)
The assumption it rests on. Health plans accept 25% downside cap without demanding 15-20% PMPM reduction to compensate — the engine put the probability at 0.7.
| Investment required | $0 incremental — policy change executed by existing legal, finance, and account management teams within current $14M annual burn |
| Expected return | 5.2× on zero incremental investment — derived from $4.2M FY2026 bookings protected relative to status-quo downside exposure |
| Revenue, year 1 | $57.8M ARR (25% at-risk share = $15.5M at-risk revenue vs $23.6M status quo) |
| Revenue, year 2 | $61.4M ARR (assuming 80% contract renewal at 25% cap) |
| Revenue, year 3 | $68.2M ARR (assuming 85% renewal and 10% PMPM stabilization) |
| Exit criteria | Abandon this move if >3 of 8 Q4 2026 contract renewals demand >15% PMPM reduction to accept 25% cap, OR if outcome-prediction accuracy falls below 70% on 10k cohort by Month 9; pivot to fixed-fee PMPM model with optional 15% upside sharing only |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to Growth Portfolio Framework, one of 29 engagements the platform runs. For 数字健康公司 it works through at-risk revenue share, engagement rate, gross margin and logo churn, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. 在此阅读完整报告 if you would rather see the depth first.
把持久性明确标价。会衰减的回报需要写明半衰期；一旦每个选项都带上这个，不同跨度的选项就能比较，而非凭感觉。
通常投最强的，因为边际美元在那里复利。修最弱的部分，只有当它构成对最强部分的约束时才有必要，否则不值得。
那就看可逆性。两个选项回报相近时，选能停的，因为买到的信息价值超过估算差值。
Materially, yes. Outcomes risk is being signed faster than the company can learn whether it can carry it — a 12-month measurement window against an 11-month sales cycle — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are at-risk revenue share, engagement rate, gross margin, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on at-risk revenue share and engagement rate. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.
English · Español · Deutsch · Português · Français · Italiano · Nederlands · 日本語 · 한국어 · 中文 · Polski · Svenska · Türkçe · العربية · Tiếng Việt · ไทย · हिन्दी · עברית